Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models
These studies collectively show that this evolutionarily stable region can be targeted by vaccination strategies, and future work will test if these vaccines, alone or in combination, can result in reduced disease burden in animal challenge models.
Authors
- Petros C. Karakousis (ORCID: https://orcid.org/0000-0003-1338-9206)
- Yinan Hui
- Samuel K. Ayeh
- Courtney Schill (ORCID: https://orcid.org/0000-0002-2841-7612)
- James T. Gordy (ORCID: https://orcid.org/0000-0003-2588-0756)
- Richard B. Markham (ORCID: https://orcid.org/0000-0003-3527-9147)
- Kaitlyn Fessler
- Aakanksha R. Kapoor (ORCID: https://orcid.org/0000-0002-7386-2678)
- Avinaash K. Sandhu (ORCID: https://orcid.org/0000-0003-4501-1478)
- Styliani Karanika (ORCID: https://orcid.org/0000-0003-2387-6075)
- Jiaqi Zhang (ORCID: https://orcid.org/0000-0001-7782-8031)
- Tianyin Wang (ORCID: https://orcid.org/0000-0002-0208-1794)
- Yangchen Li
- Jacob Meza
- Rowan E. Bates
- Alannah D. Taylor
- Elizabeth M. Glass
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-02-22
- DOI
- https://doi.org/10.3390/vaccines13030220
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Allergy and Infectious Diseases